Enocitabine is a nucleoside analog, and is a potent DNA replication inhibitor, and a DNA chain terminator. Enocitabine inhibits the replication of human cytomegalovirus. Enocitabine has antileukemic and antiviral activities^[1][2][3].

DNA replication^[1]; CMV^[3]

Enocitabine is resistant to deamination because Enocitabine bears a highly lipophilic group at the 4-amino position of the cytosine moiety of cytarabine^[1].
The combined effects of Pirarubicin and Enocitabine on HeLa S3 human uterine cervix carcinoma and K562 human myelocytic leukemia cells are determined by enhancement of their cytotoxic activities. Enocitabine or etoposide shows synergistic effects on HeLa S3 and K562 cells^[2].
In the presence of Enocitabine, triphosphate forms of the nucleoside analogs are detected in the human cytomegalovirus (HCMV)-infected cells, and synthesis of HCMV DNA is strongly suppressed^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

565.78

C₃₁H₅₅N₃O₆

55726-47-1

固體

White to off-white

依諾他濱；依諾他賓

Room temperature in continental US; may vary elsewhere.

• [1]. Hamada A, et al. Clinical pharmacokinetics of cytarabine formulations.Clin Pharmacokinet. 2002;41(10):705-18.  [Content Brief]

  [2]. Nagasawa M, et al.In vitro combined effects of pirarubicin (THP) and various antitumor drugs on human tumor cell lines. Gan To Kagaku Ryoho. 1990 Apr;17(4 Pt 1):633-8.  [Content Brief]

  [3]. Nakamura K, et al. Antiviral effect of antileukemic drugs N4-behenoyl-1-beta-D-arabinofuranosylcytosine (BH-AC) and 2,2'-anhydro-1-beta-D-arabinofuranosylcytosine (cyclo-C) against human cytomegalovirus. J Med Virol. 1990 Jun;31(2):141-7.  [Content Brief]